To Get Help Now
Click Here
 
Today's Date:

Lawsuits Claim LYMERix Caused Treatment-Resistant Arthritis

AddThis Social Bookmark Button

 

Two lawsuits filed against GlaxoSmithKline LLC by New York plaintiff Teri Fay and New Jersey plaintiff Gregory Pryslak allege that the Lyme disease vaccination LYMERix caused treatment-resistant Lyme arthritis.

 

 Furthermore, the complaints allege that GSK knew about the risks that patients with a certain genetic trait were more likely to develop the arthritis, yet they continued to market the vaccine until it was removed from the market in 2002. The plaintiffs say LYMERix hit the market in 1998, and they both received the vaccine in the late 1990s. Both allege they were later diagnosed with Post-Lyme disease treatment disorder also called treatment-resistant Lyme arthritis, Law360 reports.

 

 “Defendants knew of the subject product’s defective and unreasonably dangers nature….but continued to design, develop, manufacture, market, distribute and sell it so as to maximize sales and profits at the expense of the health and safety of the public,” the plaintiffs say.

 

 The lawsuits allege that even after adverse side effects began to be reported, GSK continued to market the vaccine’s safety and efficacy. The suits also allege that GSK performed a “meaningless” experiment to attempt to prove the safety of the vaccine by giving the drug to mice prone to arthritis, even though they knew the mice did not carry the genetic blood trait that interacts with the vaccine to cause arthritis.

 

 

The lawsuits seek punitive and compensatory damages for fraud, negligence, negligent misrepresentation, breach of warranty and unjust enrichment.

 


 

Normal
0

false
false
false

EN-US
X-NONE
X-NONE

/* Style Definitions */
table.MsoNormalTable
{mso-style-name:”Table Normal”;
mso-tstyle-rowband-size:0;
mso-tstyle-colband-size:0;
mso-style-noshow:yes;
mso-style-priority:99;
mso-style-qformat:yes;
mso-style-parent:””;
mso-padding-alt:0in 5.4pt 0in 5.4pt;
mso-para-margin:0in;
mso-para-margin-bottom:.0001pt;
mso-pagination:widow-orphan;
font-size:11.0pt;
font-family:”Calibri”,”sans-serif”;
mso-ascii-font-family:Calibri;
mso-ascii-theme-font:minor-latin;
mso-fareast-font-family:”Times New Roman”;
mso-fareast-theme-font:minor-fareast;
mso-hansi-font-family:Calibri;
mso-hansi-theme-font:minor-latin;}

Two lawsuits filed against GlaxoSmithKline LLC by New York plaintiff Teri Fay and New Jersey plaintiff Gregory Pryslak allege that the Lyme disease vaccination LYMERix caused treatment-resistant Lyme arthritis.

Furthermore, the complaints allege that GSK knew about the risks that patients with a certain genetic trait were more likely to develop the arthritis, yet they continued to market the vaccine until it was removed from the market in 2002. The plaintiffs say LYMERix hit the market in 1998, and they both received the vaccine in the late 1990s. Both allege they were later diagnosed with Post-Lyme disease treatment disorder also called treatment-resistant Lyme arthritis, Law360 reports.

“Defendants knew of the subject product’s defective and unreasonably dangers nature….but continued to design, develop, manufacture, market, distribute and sell it so as to maximize sales and profits at the expense of the health and safety of the public,” the plaintiffs say.

The lawsuits allege that even after adverse side effects began to be reported, GSK continued to market the vaccine’s safety and efficacy. The suits also allege that GSK performed a “meaningless” experiment to attempt to prove the safety of the vaccine by giving the drug to mice prone to arthritis, even though they knew the mice did not carry the genetic blood trait that interacts with the vaccine to cause arthritis.

The lawsuits seek punitive and compensatory damages for fraud, negligence, negligent misrepresentation, breach of warranty and unjust enrichment.


breakinglawsuitnews.com disclaimer: This article: Lawsuits Claim LYMERix Caused Treatment-Resistant Arthritis was posted on Thursday, August 9th, 2012 at 8:29 pm at breakinglawsuitnews.com and is filed under Defective Drug Lawsuits.

« »

Comments are closed.